Dissertations from Karolinska Institutet - Published by Karolinska Institutet Karolinska Institutet

Sök och bläddra bland Karolinska Institutets avhandlingar

1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010		Info

Doktorsavhandling vid Karolinska Institutet
Fiala, Christian Improving medical abortion : Using mifepristone in combination with a prostaglandin analogue Fredagen den 7 oktober 2005, kl. 9.00. Skandiasalen, Astrid Lindgrens Barnsjukhus, Karolinska Universitetssjukhuset, Solna.

ISBN: 91-7140-458-9

Diss: 05:384

Abstract:

Background: Induced abortion is still a major health problem in the world and the most frequently performed intervention in Obstetrics and Gynaecology with an estimated total of 46 millions worldwide each year. Medical abortion with mifepristone and prostaglandin was first introduced in 1988, and is now approved in 29 countries. It has recently been included in the List of Essential Medicines by WHO. However, the regimen has undergone only minor changes since the introduction.

The overall aim of the thesis was to evaluate possible improvements in medical abortion using mifepristone in combination with the prostaglandin E1 analogue misoprostol. Different aspects of the treatment were studied including criteria for evaluation of complete abortion, acceptability, pain management and a new form of slow release misoprostol.

Study I + II: Healthy women with an unwanted pregnancy who had chosen medical abortion were recruited. The use of ultrasound and hCG for the interpretation of the follow-up examination (n=217) was evaluated in the first study and acceptance of home use of misoprostol (n=100) in the second. hCG proved to be a more reliable indicator for assessment of outcome when compared to ultrasound, especially in very early pregnancy. Women gave a high priority to the free choice of the place of intake of misoprostol. Almost all women who had chosen home use of misoprostol were satisfied or very satisfied with their choice.

Study III: Women undergoing medical abortion in second trimester (n=74) were randomized to receive a prophylactic pain treatment together with misoprostol either including a NonSteroidal Anti-Inflammatory Drug (NSAID) or without NSAID. There was no significant difference between the two groups in the induction-to-abortion interval or the total doses of misoprostol needed. The frequency of surgical intervention was similar. Women in the group treated with NSAID required significantly less opiates.

Study IV + V: A new slow-release form of misoprostol was compared with conventional oral misoprostol in women undergoing surgical abortion. Pharmacokinetics (n=31) and uterine contractions (n=30) were analysed. The SR misoprostol demonstrated lower peak plasma levels but longer lasting elevation in plasma levels than conventional oral misoprostol. SR misoprostol acts less on pain inducing uterine tonus than orally administered conventional misoprostol but leads to more regular uterine contractions.

Conclusion: The current protocols for medical abortion have the potential for further improvement. The need for surgical intervention could be reduced with criteria for the interpretation of hCG and ultrasound findings at the follow up. Administration of misoprostol at home, gives women more autonomy in the course of medical abortion. NSAIDs do not prolong the time to expulsion in medical abortion and should be integral part of pain treatment, even given as prophylactic. The new oral slow release form of misoprostol may have potential to improve medical abortion as indicated by the effects on uterine contractility and pharmacokinetics.

Keywords: Medical abortion, mifepristone, misoprostol, slow release, home use, hCG, ultrasound, verification of expulsion, non-steroidal anti-inflammatory drug, pain relief, second trimester, uterine contractility, acceptability

List of papers

	Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K Eur J Obstet Gynecol Reprod Biol, 2003; 109(2): 190-5
	Acceptability of home-use of misoprostol in medical abortion. Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K Contraception, 2004; 70(5): 387-92
	The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K Hum Reprod, 2005; Aug 11: Epub ahead of print In Print
	Effects of slow release misoprostol on uterine contractility in early pregnancy. Fiala C, Aronsson A, Stephansson O, Gemzell-Danielsson K Hum Reprod, 2005; 20(9): 2648-52. Epub 2005 May 26
	Pharmacokinetics of a novel oral slow-release form of misoprostol. Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K Hum Reprod, 2005; Jul 29: Epub ahead of print

Doktorsavhandling vid Karolinska Institutet

Fiala, Christian

Relaterat

Mer från biblioteket